These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 24204198)

  • 1. Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab.
    Iida M; Brand TM; Starr MM; Li C; Huppert EJ; Luthar N; Pedersen MW; Horak ID; Kragh M; Wheeler DL
    Neoplasia; 2013 Oct; 15(10):1196-206. PubMed ID: 24204198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.
    Iida M; Brand TM; Starr MM; Huppert EJ; Luthar N; Bahrar H; Coan JP; Pearson HE; Salgia R; Wheeler DL
    Mol Cancer; 2014 Oct; 13():242. PubMed ID: 25344208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab.
    Brand TM; Dunn EF; Iida M; Myers RA; Kostopoulos KT; Li C; Peet CR; Wheeler DL
    Cancer Biol Ther; 2011 Sep; 12(5):436-46. PubMed ID: 21725209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab.
    Iida M; Brand TM; Campbell DA; Starr MM; Luthar N; Traynor AM; Wheeler DL
    Cancer Biol Ther; 2013 Jun; 14(6):481-91. PubMed ID: 23760490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.
    Sánchez-Martín FJ; Bellosillo B; Gelabert-Baldrich M; Dalmases A; Cañadas I; Vidal J; Martinez A; Argilés G; Siravegna G; Arena S; Koefoed K; Visa L; Arpí O; Horak ID; Iglesias M; Stroh C; Kragh M; Rovira A; Albanell J; Tabernero J; Bardelli A; Montagut C
    Clin Cancer Res; 2016 Jul; 22(13):3260-7. PubMed ID: 26888827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab.
    Iida M; Bahrar H; Brand TM; Pearson HE; Coan JP; Orbuch RA; Flanigan BG; Swick AD; Prabakaran PJ; Lantto J; Horak ID; Kragh M; Salgia R; Kimple RJ; Wheeler DL
    Mol Cancer Ther; 2016 Sep; 15(9):2175-86. PubMed ID: 27422810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sym004, a novel anti-EGFR antibody mixture, augments radiation response in human lung and head and neck cancers.
    Huang S; Peet CR; Saker J; Li C; Armstrong EA; Kragh M; Pedersen MW; Harari PM
    Mol Cancer Ther; 2013 Dec; 12(12):2772-81. PubMed ID: 24130052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer.
    Hu S; Dai H; Li T; Tang Y; Fu W; Yuan Q; Wang F; Lv G; Lv Y; Fan X; Zhang S; Jin R; Shen Y; Lin F; Ye X; Ding M; Yang Y; Lei C
    Cancer Lett; 2016 Nov; 382(1):32-43. PubMed ID: 27569653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical efficacy of Sym004, novel anti-EGFR antibody mixture, in esophageal squamous cell carcinoma cell lines.
    Fukuoka S; Kojima T; Koga Y; Yamauchi M; Komatsu M; Komatsuzaki R; Sasaki H; Yasunaga M; Matsumura Y; Doi T; Ohtsu A
    Oncotarget; 2017 Feb; 8(7):11020-11029. PubMed ID: 28038457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
    Ciardiello F; Bianco R; Caputo R; Caputo R; Damiano V; Troiani T; Melisi D; De Vita F; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2004 Jan; 10(2):784-93. PubMed ID: 14760102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor.
    Iida M; Brand TM; Campbell DA; Li C; Wheeler DL
    Oncogene; 2013 Feb; 32(6):759-67. PubMed ID: 22430206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation.
    Napolitano S; Martini G; Martinelli E; Belli V; Parascandolo A; Laukkanen MO; Sforza V; Morgillo F; Ciardiello D; Ciardiello F; Troiani T
    Oncotarget; 2017 Sep; 8(40):67592-67604. PubMed ID: 28978055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
    Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
    Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer.
    Dienstmann R; Patnaik A; Garcia-Carbonero R; Cervantes A; Benavent M; Roselló S; Tops BB; van der Post RS; Argilés G; Skartved NJ; Hansen UH; Hald R; Pedersen MW; Kragh M; Horak ID; Braun S; Van Cutsem E; Tolcher AW; Tabernero J
    Cancer Discov; 2015 Jun; 5(6):598-609. PubMed ID: 25962717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.
    Benavente S; Huang S; Armstrong EA; Chi A; Hsu KT; Wheeler DL; Harari PM
    Clin Cancer Res; 2009 Mar; 15(5):1585-92. PubMed ID: 19190133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab.
    Wheeler DL; Iida M; Kruser TJ; Nechrebecki MM; Dunn EF; Armstrong EA; Huang S; Harari PM
    Cancer Biol Ther; 2009 Apr; 8(8):696-703. PubMed ID: 19276677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells.
    Oliveras-Ferraros C; Cufí S; Queralt B; Vazquez-Martin A; Martin-Castillo B; de Llorens R; Bosch-Barrera J; Brunet J; Menendez JA
    Br J Cancer; 2012 Apr; 106(8):1406-14. PubMed ID: 22491422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AXL mediates resistance to cetuximab therapy.
    Brand TM; Iida M; Stein AP; Corrigan KL; Braverman CM; Luthar N; Toulany M; Gill PS; Salgia R; Kimple RJ; Wheeler DL
    Cancer Res; 2014 Sep; 74(18):5152-64. PubMed ID: 25136066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.
    Keir ST; Chandramohan V; Hemphill CD; Grandal MM; Melander MC; Pedersen MW; Horak ID; Kragh M; Desjardins A; Friedman HS; Bigner DD
    J Neurooncol; 2018 Jul; 138(3):489-498. PubMed ID: 29564747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.